000881
Stock Abbreviation: CGN Nuclear Technology
Announcement Number: 2026-040
CGN Nuclear Technology Development Co., Ltd.
Resolution Announcement of the Fourth Meeting of the Eleventh Board of Directors
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and that there are no false representations, misleading statements, or material omissions.
I. Convening of the Board Meeting
-
The notice for the Fourth Meeting of the Eleventh Board of Directors of CGN Nuclear Technology Development Co., Ltd. (hereinafter referred to as the "Company") (hereinafter referred to as the "Meeting") was issued via email on July 3, 2026.
-
The Meeting was held on July 9, 2026, at 9:00 AM in Meeting Room 881, North Building, CGN Building, No. 2002 Shennan Avenue, Futian District, Shenzhen, through a combination of on-site and written voting methods.
-
A total of 9 directors were eligible to attend the Meeting, and 9 directors actually attended (of which: 2 directors attended by proxy. Directors Cui Wei and Mou Wenjun were unable to attend in person due to work and personal reasons and respectively authorized Directors Zheng Guoping and He Fei to attend; 5 directors attended via written voting, namely Sheng Guofu, Zheng Guoping, Huang Xiaoyan, Kang Xiaoyue, and Wang Man). 0 directors were absent.
-
The Meeting was presided over by Mr. Sheng Guofu, Chairman of the Company. The Company's Board Secretary and some senior management personnel attended the meeting.
-
The convening and holding of this Meeting comply with the relevant laws, administrative regulations, departmental rules, normative documents, and the "Articles of Association" of the Company.
II. Deliberation and Voting of the Board Meeting
After deliberation and voting by the directors present, the following resolutions were formed at the Meeting:
- Resolution on the Proposal for the Establishment of a New Subsidiary in Shanghai by CGN Nuclear Technology
After deliberation, the Board of Directors agreed to establish a sales subsidiary in Shanghai, tentatively named CGN HeZhi Medical Technology Co., Ltd. (subject to approval by the Administration for Market Regulation), with a registered capital of RMB 2 million.
This proposal was pre-approved by the Strategic Committee of the Eleventh Board of Directors at its Second Meeting in 2026.
Voting results: 9 votes in favor, 0 votes against, 0 abstentions, 0 recused votes.
Resolution outcome: Approved.
- Resolution on the Proposal for the Investment Decision of the Oxygen-18 Water Production Project
After deliberation, the Board of Directors approved the investment decision for the "Oxygen-18 Water Production Project." The total investment for the project shall not exceed RMB 125.03 million, of which self-owned funds shall not exceed RMB 62.80 million. It was agreed to establish a wholly-owned subsidiary, CGN Molecular Technology Co., Ltd. (tentative name, subject to approval by the industrial and commercial authorities), as the investment entity with a registered capital of RMB 62.80 million.